Ribavirin inhibits Borna disease virus proliferation and fatal neurological diseases in neonatally infected gerbils

Antiviral Research

Volumn 80, Issue 3, 2008, Pages 380-384

  Lee, Byeong Jae ^a   Matsunaga, Hidenori ^b   Ikuta, Kazuyoshi ^a,c   Tomonaga, Keizo ^a,d  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Borna disease virus; Mongolian gerbils; Neurological disorder; Ribavirin

Indexed keywords

CYTOKINE; RIBAVIRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BORNA DISEASE VIRUS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; FATALITY; GERBIL; MICROGLIA; NEUROLOGIC DISEASE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANIMALS, NEWBORN; ANTIVIRAL AGENTS; BORNA DISEASE; BORNA DISEASE VIRUS; BRAIN; FEMALE; GERBILLINAE; MALE; NERVOUS SYSTEM DISEASES; RIBAVIRIN; RODENT DISEASES; VIRUS REPLICATION;

BORNA DISEASE VIRUS; GERBILLINAE; MERIONES UNGUICULATUS;

EID: 56349117938     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.08.001     Document Type: Article

References (31)

1. Bajramovic J.J., Syan S., Brahic M., de la Torre J.C., and Gonzalez-Dunia D. 1-beta-d-Arabinofuranosylcytosine inhibits Borna disease virus replication and spread. J. Virol. 76 (2002) 6268-6276
2. Bajramovic J.J., Volmer R., Syan S., Pochet S., and Gonzalez-Dunia D. 2′-Fluoro-2′-deoxycytidine inhibits Borna disease virus replication and spread. Antimicrob. Agents Chemother. 48 (2004) 1422-1425
3. Billich C., Sauder C., Frank R., Herzog S., Bechter K., Takahashi K., Peters H., Staeheli P., and Schwemmle M. High-avidity human serum antibodies recognizing linear epitopes of Borna disease virus proteins. Biol. Psychiatry 51 (2002) 979-987
4. Bode L., Dietrich D.E., Stoyloff R., Emrich H.M., and Ludwig H. Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 349 (1997) 178-179
5. Bougie I., and Bisaillon M. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J. Biol. Chem. 279 (2004) 22124-22130
6. Cameron C.E., and Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr. Opin. Infect. Dis. 14 (2001) 757-764
7. Carbone K.M. Borna disease virus and human disease. Clin. Microbiol. Rev. 14 (2001) 513-527
8. Carlsson T., Quist A., and Weiland O. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J. Med. Virol. 80 (2008) 803-807
9. Crotty S., Cameron C.E., and Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6895-6900
10. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., and Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6 (2000) 1375-1379
11. Engler S., Flechtenmacher C., Wiedemann K.H., Gugler R., Stremmel W., and Kallinowski B. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J. Viral. Hepat. 11 (2004) 60-68
12. Hallensleben W., Zocher M., and Staeheli P. Borna disease virus is not sensitive to amantadine. Arch. Virol. 142 (1997) 2043-2048
13. Hwang I.K., Yoo K.Y., Park J.K., Nam Y.S., Lee I.S., Kang J.H., Choi S.Y., Lee J.Y., Kang T.C., and Won M.H. Ischemia-related changes of adrenocorticotropic hormone immunoreactivity and its protective effect in the gerbil hippocampus after transient forebrain ischemia. Neuroscience 126 (2004) 871-877
14. Ikuta K., Hagiwara K., Taniyama H., and Nowotny N. Epidemiology and infection of natural animal hosts. In: Carbone K.M. (Ed). Borna Disease Virus and its Role in Neurobehavioral Disease (2002), ASM Press, Washington, DC 87-123
15. Ikuta K., Ibrahim M.S., Kobayashi T., and Tomonaga K. Borna disease virus and infection in humans. Front. Biosci. 7 (2002) D470-D495
16. Jordan I., Briese T., Averett D.R., and Lipkin W.I. Inhibition of Borna disease virus replication by ribavirin. J. Virol. 73 (1999) 7903-7906
17. Lee B.J., Watanabe M., Kamitani W., Baba S., Yamashita M., Kobayashi T., Tomonaga K., and Ikuta K. Age- and host-dependent control of Borna disease virus spread in the developing brains of gerbils and rats. Microbes Infect. 5 (2003) 1195-1204
18. Liu M.F., Ning Q., Pope M., Mosmann T., Leibowitz J., Ding J.W., Fung L.S., Rotstein O., Gorczynski R., and Levy G.A. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. Adv. Exp. Med. Biol. 440 (1998) 415-423
19. Ludwig H., and Bode L. Borna disease virus: new aspects on infection, disease, diagnosis and epidemiology. Rev. Sci. Tech. 19 (2000) 259-288
20. Mizutani T., Inagaki H., Araki K., Kariwa H., Arikawa J., and Takashima I. Inhibition of Borna disease virus replication by ribavirin in persistently infected cells. Arch. Virol. 143 (1998) 2039-2044
21. Ning Q., Brown D., Parodo J., Cattral M., Gorczynski R., Cole E., Fung L., Ding J.W., Liu M.F., Rotstein O., Phillips M.J., and Levy G. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J. Immunol. 160 (1998) 3487-3493
22. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res. 107 (2005) 165-171
23. Rott R., and Becht H. Natural and experimental Borna disease in animals. Curr. Top. Microbiol. Immunol. 190 (1995) 17-30
24. Severson W.E., Schmaljohn C.S., Javadian A., and Jonsson C.B. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77 (2003) 481-488
25. Solbrig M.V., Schlaberg R., Briese T., Horscroft N., and Lipkin W.I. Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats. Antimicrob. Agents Chemother. 46 (2002) 2287-2291
26. Stitz L., Planz O., and Bilzer T. Lack of antiviral effect of amantadine in Borna disease virus infection. Med. Microbiol. Immunol. 186 (1998) 195-200
27. Tomoda A., Nomura K., Shiraishi S., Hamada A., Ohmura T., Hosoya M., Miike T., Sawaishi Y., Kimura H., Takashima H., Tohda Y., Mori K., Kato Z., Fukushima A., Nishio H., Nezu A., and Nihei K. Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan. Brain Dev. 25 (2003) 514-517
28. Tomonaga K., Kobayashi T., and Ikuta K. Molecular and cellular biology of Borna disease virus infection. Microbes Infect. 4 (2002) 491-500
29. Volmer R., Bajramovic J.J., Schneider U., Ufano S., Pochet S., and Gonzalez-Dunia D. Mechanism of the antiviral action of 1-beta-d-arabinofuranosylcytosine on Borna disease virus. J. Virol. 79 (2005) 4514-4518
30. Watanabe M., Lee B.J., Kamitani W., Kobayashi T., Taniyama H., Tomonaga K., and Ikuta K. Neurological diseases and viral dynamics in the brains of neonatally Borna disease virus-infected gerbils. Virology 282 (2001) 65-76
31. Watanabe M., Lee B.J., Yamashita M., Kamitani W., Kobayashi T., Tomonaga K., and Ikuta K. Borna disease virus induces acute fatal neurological disorders in neonatal gerbils without virus- and immune-mediated cell destructions. Virology 310 (2003) 245-253